A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS—Individuals (n = 476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of ≤6.0 mmol/l (≤108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C ≤7.0%, risk of hypoglycemia, and body weight. RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was −1.58 (P < 0.001). CONCLUSIONS—Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The decrease in A1C from triple therapy was greater at 6 months than that of conventional therapy and the superiority was maintained at 3 years.1061”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1061]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Research works printed but not linked: 1
- Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 66:193–201, 2004 · DOI · Paper page
Cited by
Items 101–200 of 627
Insulin Analogs—Are They Worth It? Yes!
Grunberger, G. (2014) · Diabetes Care · doi:10.2337/dc14-0031 · Cited by 86
Hirsch, I. B., Bode, B., Courreges, J.-P., Dykiel, P., Franek, E., Hermansen, K., King, A., Mersebach, H., & Davies, M. (2012) · Diabetes Care · doi:10.2337/dc11-2503 · Cited by 76
Self-citationNice insulins, pity about the evidence
Holleman, F., & Gale, E. A. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0763-4 · Cited by 78
Hong, E. S., Khang, A. R., Yoon, J. W., Kang, S. M., Choi, S. H., Park, K. S., Jang, H. C., Shin, H., Walford, G. A., & Lim, S. K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01600.x · Cited by 81
Cooke, C. E., Lee, H. Y., Tong, Y. P., & Haines, S. T. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903421994 · Cited by 78
Insulin degludec: overview of a novel ultra long‐acting basal insulin
Gough, S. C. L., Harris, S. B., Woo, V. C., & Davies, M. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12052 · Cited by 81
Self-citationThe Chemical Synthesis of Insulin: An Enduring Challenge
Karas, J. A., Wade, J. D., & Hossain, M. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01251 · Cited by 75
Dornhorst, A., Lüddeke, H.-J., Sreenan, S., Kozlovski, P., Hansen, J. B., Looij, B. J., Meneghini, L., & on behalf of the PREDICTIVE Study Group (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01715.x · Cited by 75
Self-citationHypoglycemia Rates with Basal Insulin Analogs
Little, S. A., Shaw, J., & Home, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0022 · Cited by 72
Self-citationRolla, A. R. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.022 · Cited by 77
Arnolds, S., Kuglin, B., Kapitza, C., & Heise, T. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02470.x · Cited by 69
Insulin analogues: an example of applied medical science
Sheldon, B., Russell‐Jones, D., & Wright, J. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01015.x · Cited by 69
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66
lov, K. R., Tamer, S. C., Clauson, P., & Karl, D. M. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727040-00007 · Cited by 70
Self-citationClinical utility of insulin and insulin analogs
Şanlioğlu, A. D., Altunbaş, H., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2013) · Islets · doi:10.4161/isl.24590 · Cited by 65
Freemantle, N., Chou, E., Frois, C., Zhuo, D., Lehmacher, W., Vlajnic, A., Wang, H., Chung, H.-W., Zhang, Q., Wu, E., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009421 · Cited by 60
Evolution of Insulin Development: Focus on Key Parameters
Tibaldi, J. M. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0034-8 · Cited by 73
Controlled release of biologics for the treatment of type 2 diabetes
Gilroy, C. A., Luginbuhl, K. M., & Chilkoti, A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.002 · Cited by 67
Blonde, L., Meneghini, L., Peng, X., Boss, A., Rhee, K. B. L., Shaunik, A., Kumar, S. R., Balodi, S., Brulle-Wohlhueter, C., & McCrimmon, R. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0413-5 · Cited by 70
Insulin's 85th anniversary—An enduring medical miracle
Heller, S. R., Kozlovski, P., & Kurtzhals, P. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.04.001 · Cited by 70
Uncovering undetected hypoglycemic events
Unger, J. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s29367 · Cited by 71
Vaag, A., & Lund, S. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0022 · Cited by 62
Hallschmid, M., Jauch-Chara, K., Korn, O., Mölle, M., Rasch, B., Born, J., Schultes, B., & Kern, W. (2010) · Diabetes · doi:10.2337/db09-1493 · Cited by 61
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus
Rossetti, P., Porcellati, F., Fanelli, C. G., Perriello, G., Torlone, E., & Bolli, G. B. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801900777 · Cited by 65
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 63
Meneghini, L., Kesavadev, J., Demissie, M., Nazeri, A., & Hollander, P. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12083 · Cited by 65
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Blak, B. T., Smith, H. T., Hards, M., Maguire, A., & Gimeno, V. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03694.x · Cited by 64
Wang, J., Geiss, L. S., Williams, D. E., & Gregg, E. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134917 · Cited by 59
Strange, P. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100412 · Cited by 59
Optimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 68
Gaal, L. F. V., Gutkin, S. W., & Nauck, M. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0804 · Cited by 65
Addressing Cultural Barriers to the Successful Use of Insulin in Hispanics with Type 2 Diabetes
Campos, C. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e3180f609c4 · Cited by 64
Home, P. (2007) · Diabetologia · doi:10.1007/s00125-007-0653-9 · Cited by 58
Self-citationVinik, A. I. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.005 · Cited by 61
Insulin analogs: Glimpse on contemporary facts and future prospective
Sharma, A. K., Taneja, G., Kumar, A. R., Sahu, M., Sharma, G., Kumar, A., Sardana, S., & Deep, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.01.011 · Cited by 61
Challenges Associated with Insulin Therapy in Type 2 Diabetes Mellitus
Edelman, S. V., & Pettus, J. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.003 · Cited by 64
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Benefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 59
Fadini, G. P., de Kreutzenberg, S. V., Mariano, V., Boscaro, E., Bertolini, F., Mancuso, P., Quarna, J., Marescotti, M. C., Agostini, C., Tiengo, A., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01396.x · Cited by 55
Insulin treatment for type 2 diabetes: When to start, which to use
Hamaty, M. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10051 · Cited by 55
Common Standards of Basal Insulin Titration in T2DM
Arnolds, S., Heise, T., Flacke, F., & Sieber, J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700323 · Cited by 55
Dornhorst, A., Lüddeke, H. ‐., Koenen, C., Merilainen, M. J., King, A. B., Robinson, A., Sreenan, S., & PREDICTIVE Study Group (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00816.x · Cited by 54
Garber, A. J., Clauson, P., Pedersen, C. B., & Kølendorf, K. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01414.x · Cited by 53
Self-citationPorcellati, F., Lucidi, P., Cioli, P., Candeloro, P., Marinelli Andreoli, A., Marzotti, S., Ambrogi, M., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc14-0649 · Cited by 52
Insulin Therapy and Type 2 Diabetes: Management of Weight Gain
McFarlane, S. I. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00063.x · Cited by 58
Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.067926 · Cited by 57
Self-citationEsposito, K., Ciotola, M., Maiorino, M. I., Gualdiero, R., Schisano, B., Ceriello, A., Beneduce, F., Feola, G., & Giugliano, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00005 · Cited by 51
Khunti, K., Caputo, S., Damci, T., Dzida, G. J., Ji, Q., Kaiser, M., Karnieli, E., Liebl, A., Ligthelm, R. J., Nazeri, A., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01665.x · Cited by 51
Self-citationTreating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
McCall, A. L., & Farhy, L. S. (2013) · PubMed · Cited by 80
Riddle, M. C., Vlajnic, A., Zhou, R., & Rosenstock, J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12096 · Cited by 52
Insulin Glargine: a review 8 years after its introduction
Goykhman, S., Drincic, A., Desmangles, J. C., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49
Insulins: Past, Present, and Future
Borgoño, C. A., & Zinman, B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.002 · Cited by 56
Addressing hyperglycemia from hospital admission to discharge
Moghissi, E. S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903566822 · Cited by 51
Hermansen, K., Mortensen, L. S., & Hermansen, M.-L. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1815 · Cited by 57
Self-citationThe Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
Pi-Sunyer, X. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1785 · Cited by 53
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.006 · Cited by 48
Rosenstock, J., Rodbard, H. W., Bain, S. C., D’Alessio, D. A., Seufert, J., Thomsen, A. B., Svendsen, C. B., & DeVries, J. H. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.008 · Cited by 53
Insulin Detemir: A Review of its Use in the Management of Diabetes Mellitus
Keating, G. M. (2012) · Drugs · doi:10.2165/11470200-000000000-00000 · Cited by 55
Pontiroli, A. E., Miele, L., & Morabito, A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01543.x · Cited by 48
Role of Insulin Signaling in Maintaining Energy Homeostasis
Sharma, M. D., Garber, A. J., & Farmer, J. A. (2008) · Endocrine Practice · doi:10.4158/ep.14.3.373 · Cited by 50
Insulin analogs and pregnancy: an update
Torlone, E., Cianni, G. D., Mannino, D., & Lapolla, A. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0130-7 · Cited by 51
DAILEY, G. E., Admane, K., Mercier, F., & Owens, D. R. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0063 · Cited by 49
McCall, A. L., & Kovatchev, B. P. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300102 · Cited by 51
Miser, W. F., Arakaki, R. F., Jiang, H. H., Scism-Bacon, J. L., Anderson, P. W., & Fahrbach, J. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.05.001 · Cited by 49
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 49
Frier, B. M., Russell-Jones, D. L., & Heise, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12106 · Cited by 49
Severe hypoglycemia risk with long-acting insulin analogs vs neutral protamine Hagedorn insulin
Bradley, M. C., Chillarige, Y., Lee, H., Wu, X., Parulekar, S., Muthuri, S., Wernecke, M., MaCurdy, T. E., Kelman, J. A., & Graham, D. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.9176 · Cited by 45
Davies, M. J., Dereziński, T., Pedersen, C. B., & Clauson, P. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0282 · Cited by 46
Self-citationThe Future of Basal Insulin Supplementation
Simon, A. C. R., & DeVries, J. H. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0251 · Cited by 47
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions
Perreault, L., Vincent, L., Neumiller, J. J., & Cavaiola, T. S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.03.180162 · Cited by 49
Alsahli, M., & Gerich, J. E. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.07.002 · Cited by 53
Sélam, J.-L., Koenen, C., Weng, W., & Meneghini, L. (2008) · Current Medical Research and Opinion · doi:10.1185/030079907x242755 · Cited by 48
Goldman, J. D., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 45
Owens, D. R., Traylor, L., Dain, M., & Landgraf, W. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.003 · Cited by 41
Insulin analogues in children with Type 1 diabetes: a 52‐week randomized clinical trial
Thalange, N. K. S., Bereket, A., Larsen, J. R., Hiort, L. C., & Peterkova, V. A. (2012) · Diabetic Medicine · doi:10.1111/dme.12041 · Cited by 43
Fogelfeld, L. A., Dharmalingam, M., Robling, K., Jones, C., Swanson, D., & Jacober, S. J. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02899.x · Cited by 42
Insulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 43
Katsuno, T., Ikeda, H., Ida, K., Miyagawa, J., & Namba, M. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0293 · Cited by 40
Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control
Philis‐Tsimikas, A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.010 · Cited by 42
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Defining the Role of Insulin Detemir in Basal Insulin Therapy
Morales, J. (2007) · Drugs · doi:10.2165/00003495-200767170-00007 · Cited by 39
Insulin therapy in type 2 diabetes: what is the evidence?
van Avendonk, M. J. P., & Rutten, G. E. H. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00981.x · Cited by 38
LaSalle, J. R., & Berria, R. (2013) · PubMed · Cited by 38
Nicolucci, A., & Rossi, M. C. (2008) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 45
Hompesch, M., Ocheltree, S. M., Wondmagegnehu, E. T., Morrow, L. A., Kollmeier, A. P., Campaigne, B. N., & Jacober, S. J. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903223739 · Cited by 37
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
Giugliano, D., Maiorino, M., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · International journal of clinical practice · doi:10.1111/j.1742-1241.2010.02619.x · Cited by 41
Lloyd, A. J., Nafees, B., Barnett, A. H., Heller, S. R., Ploug, U. J., Lammert, M., & Bøgelund, M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.017 · Cited by 39
Home, P., Shen, C., Hasan, M. I., Latif, Z. A., Chen, J.-W., & González-Gálvez, G. (2014) · Diabetes Care · doi:10.2337/dc13-2413 · Cited by 36
Self-citationDiabetes care - insulin delivery in a changing world.
Marcus, A. O. (2008) · PubMed · Cited by 39
Hsu, W. C. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e318182d8a2 · Cited by 37
Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?
Niswender, K. D. (2009) · Clinical Diabetes · doi:10.2337/diaclin.27.2.60 · Cited by 37
Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?
Riddle, M. C. (2008) · Diabetes Care · doi:10.2337/dc08-s231 · Cited by 41
Glycemic Variability in Type 2 Diabetes Mellitus: Oxidative Stress and Macrovascular Complications
Johnson, E. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_13 · Cited by 38
Asche, C. V., Bode, B. W., Busk, A. K., & Nair, S. R. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01487.x · Cited by 34
Raskin, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.783 · Cited by 35
Fakhoury, W. K. H., Lockhart, I., Kotchie, R. W., Aagren, M., & LeReun, C. (2008) · Pharmacology · doi:10.1159/000149569 · Cited by 33
Begg, D. P., May-Zhang, A. A., Mul, J. D., Liu, M., D’Alessio, D. A., Seeley, R. J., & Woods, S. C. (2015) · Diabetes · doi:10.2337/db14-1364 · Cited by 34
Initiating and Intensifying Insulin Therapy in Type 2 Diabetes Mellitus
Tibaldi, J. M. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.023 · Cited by 34
Metadata
- Authors
- Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group
- Affiliations
- Aarhus University Hospital (DK)
- Leicester Royal Infirmary (GB)
- Out-Patient Clinic, NZOZ Eskulap, Gniewkowo, Poland
- Out-Patient Clinic, Novo Nordisk, Bagsværd, Denmark
- Novo Nordisk (Denmark) (DK)
- Newcastle University (GB)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 29
- Issue
- 6
- Pages
- 1269-1274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2149194615
- Cited by
- 627
- References
- 36
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 31 · 2014: 44 · 2013: 59 · 2012: 55
- FWCI
- 48.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin detemir, NPH insulin, basal insulin, type 2 diabetes, insulin-naive patients, oral glucose-lowering agents, adjunctive therapy, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain
- MeSH terms
- Insulin Detemir, Administration, Oral, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Weight Gain, Body Mass Index, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.